Pfizer
Shire adds to gastrointestinal portfolio with Pfizer compound acquisition
June 14, 2016Research and Development, Sales and Marketing Pfizer, Shire, acquisition, compound
Shire (LSE: SHP) has announced that it has acquired an investigational biologic for the treatment inflammatory bowel disease from Pfizer …
Pfizer’s leukaemia drug beats chemotherapy in Phase III trials
June 13, 2016Research and Development, Sales and Marketing Inotuzumab ozogamicin, Pfizer, acute lymphoblastic leukaemia
Pfizer (NYSE: PFE) has announced data from a pivotal Phase III trial for acute lymphoblastic leukaemia (ALL) drug, inotuzumab ozogamicin, …
Pivotal avelumab data in Merkel cell carcinoma presented at ASCO
June 6, 2016Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma
New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …
Pfizer says EMA lifts warning on its smoking cessation drug Champix
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing Champix, EMA, Pfizer, anti-smoking, drug trial
US pharma giant Pfizer (NYSE: PFE) said the European Medicines Agency has lifted a warning on its anti-smoking drug Champix …
Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug
May 23, 2016Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B
Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …
EMA to review Pfizer’s meningococcal vaccine
May 20, 2016Research and Development, Sales and Marketing EMA, Pfizer, meningitis, meningococcal vaccine, trumenba
Pfizer (NYSE: PFE) has announced that the European Medicines Agency has accepting the marketing authorisation application for its meningococcal group …
Pfizer to acquire Anacor in $5.2 billion deal
May 16, 2016Manufacturing and Production, Sales and Marketing 5.2 billion, FDA, Pfizer, acquisition, anacor, crisaborole, merger
Pfizer (NYSE: PFE) has acquired Anacor Pharmaceuticals (NASDAQ: ANAC) in a deal worth around $5.2 billion, or $99.25 per share. …
Pfizer presents positive results in meningococcal disease late-stage trials
May 13, 2016Research and Development Pfizer, Vaccine, late stage trials, meningococcal disease
Pfizer (NYSE: PFE) has announced results from two pivotal late-stage trials demonstrating the immunogenicity of Trumenba against invasive meningococcal B …
Medivation maybe mulling sale as bidding race heats up – Reports
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …
Focus: Medivation tug-of-war rumbles on
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war
Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Pfizer teams up with Wave Life Sciences for metabolic disease research
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, metabolic disease, nucelic acid therapies, partnership, wave life sciences
Pfizer (NYSE: PFE) has entered into a research, license and option agreement with Wave Life Sciences (NASDAQ: WVE) for the …
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Pfizer revenue jumps 20%; ups FY16 outlook
May 4, 2016Research and Development, Sales and Marketing Pfizer, Q1, earnings, results, revenue, sales
US pharma giant Pfizer (NYSE: PFE) reported a 20% jump in first-quarter revenue boosted by performance of its new cancer …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
In-depth: MSF takes on Pfizer, GSK
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Doctors Without Borders, GSK, Pfizer, analysis, medicins sans frontieres, patents, pneumonia
Medicins Sans Frontieres (MSF) recently stepped up their campaign to make the pneumonia vaccine more available in developing countries. Appearing …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
